In the present study, we treated patients with unresectable or metastatic melanoma with the standard dose of pembrolizumab and escalating doses of IL-2 to determine the safety of the combination and to select a dose of IL-2 for further study in combination with anti-PD-1 therapy. This evidence concerns the gene IL2 and metastatic melanoma.